Literature DB >> 28124796

Comparison of different enzyme-linked immunosorbent assay methods for avidity determination of antiphospholipid antibodies.

Lenka Fialová1, Milada Petráčková1, Oliver Kuchař1.   

Abstract

BACKGROUND: Avidity of antiphospholipid antibodies may be clinically useful as a valuable additional characteristic. The aim of this study was to compare several ELISA modifications with different chaotropic agents and calculation of avidity indices for the determination of anticardiolipin antibody (aCL) avidity.
METHODS: We examined 28 serum samples with positive IgG aCL by adapted ELISA using various concentrations of urea and sodium chloride as chaotropic agents and different dilution of sera. We tested these conditions of ELISA-a single diluted serum sample with fixed concentration of a chaotrope and a serially diluted serum in the constant concentration of a chaotropic agent.
RESULTS: We demonstrated that ELISA method for avidity determination based on a single dilution of serum in the presence of fixed concentration of chaotrope is convenient for determination of IgG aCL antibody avidity. Concentrations 6 and 8 mol/L of urea or 1 and 2 mol/L of NaCl were suitable for sufficient dissociation of immune complexes during ELISA procedure.
CONCLUSION: This way was in good agreement with more demanding procedures. Both urea and sodium chloride may be used as chaotropic agents. Reference values of avidity indices essential for interpretation of patients' results must be established individually for distinct assay conditions.
© 2017 Wiley Periodicals, Inc.

Entities:  

Keywords:  zzm321990ELISAzzm321990; anticardiolipin antibodies; antiphospholipid antibodies; avidity; chaotropic reagents; serum; sodium chloride; urea

Mesh:

Substances:

Year:  2017        PMID: 28124796      PMCID: PMC6817136          DOI: 10.1002/jcla.22121

Source DB:  PubMed          Journal:  J Clin Lab Anal        ISSN: 0887-8013            Impact factor:   2.352


  28 in total

Review 1.  Measuring agreement in method comparison studies.

Authors:  J M Bland; D G Altman
Journal:  Stat Methods Med Res       Date:  1999-06       Impact factor: 3.021

Review 2.  Antiphospholipid antibodies as non-traditional risk factors in atherosclerosis based cardiovascular diseases without overt autoimmunity. A critical updated review.

Authors:  Andrej Artenjak; Katja Lakota; Mojca Frank; Saša Čučnik; Blaž Rozman; Borut Božič; Yehuda Shoenfeld; Snezna Sodin-Semrl
Journal:  Autoimmun Rev       Date:  2012-03-10       Impact factor: 9.754

3.  Antiphospholipid antibody testing - slow progress?

Authors:  G R V Hughes; Y Shoenfeld
Journal:  Int J Clin Pract       Date:  2012-06       Impact factor: 2.503

4.  Development and application of a GuHCl-modified ELISA to measure the avidity of anti-HPV L1 VLP antibodies in vaccinated individuals.

Authors:  Joseph G Dauner; Yuanji Pan; Allan Hildesheim; Troy J Kemp; Carolina Porras; Ligia A Pinto
Journal:  Mol Cell Probes       Date:  2012-01-18       Impact factor: 2.365

5.  International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS).

Authors:  S Miyakis; M D Lockshin; T Atsumi; D W Branch; R L Brey; R Cervera; R H W M Derksen; P G DE Groot; T Koike; P L Meroni; G Reber; Y Shoenfeld; A Tincani; P G Vlachoyiannopoulos; S A Krilis
Journal:  J Thromb Haemost       Date:  2006-02       Impact factor: 5.824

6.  A protocol for determination of anticardiolipin antibodies by ELISA.

Authors:  Silvia S Pierangeli; Eon Nigel Harris
Journal:  Nat Protoc       Date:  2008       Impact factor: 13.491

7.  Important parameters for evaluation of antibody avidity by immunosorbent assay.

Authors:  Jordan D Dimitrov; Sebastien Lacroix-Desmazes; Srinivas V Kaveri
Journal:  Anal Biochem       Date:  2011-07-26       Impact factor: 3.365

8.  Assessment of IgG avidity against pertussis toxin and filamentous hemagglutinin via an adapted enzyme-linked immunosorbent assay (ELISA) using ammonium thiocyanate.

Authors:  G Almanzar; B Ottensmeier; J Liese; M Prelog
Journal:  J Immunol Methods       Date:  2012-09-27       Impact factor: 2.303

9.  Surface plasmon resonance measurements of plasma antibody avidity during primary and secondary responses to anthrax protective antigen.

Authors:  Heather E Lynch; Shelley M Stewart; Thomas B Kepler; Gregory D Sempowski; S Munir Alam
Journal:  J Immunol Methods       Date:  2013-12-04       Impact factor: 2.303

Review 10.  Laboratory methods to detect antiphospholipid antibodies.

Authors:  Steven A Krilis; Bill Giannakopoulos
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2014-11-18
View more
  7 in total

1.  Association of hepatitis B vaccine response to vitamin D supplementation and ultraviolet B (UVB) exposure during different time intervals in experimental animals.

Authors:  Sara Youssry; Thanaa Shalaby; Al-Shaimaa Maher; Hossam Ghoneim
Journal:  Immunol Res       Date:  2022-05-19       Impact factor: 4.505

2.  Intranasal Delivery of Thermostable Subunit Vaccine for Cross-Reactive Mucosal and Systemic Antibody Responses Against SARS-CoV-2.

Authors:  Khue G Nguyen; Siena M Mantooth; Maura R Vrabel; David A Zaharoff
Journal:  Front Immunol       Date:  2022-05-03       Impact factor: 8.786

3.  An epitope-based malaria vaccine targeting the junctional region of circumsporozoite protein.

Authors:  Lucie Jelínková; Hugo Jhun; Allison Eaton; Nikolai Petrovsky; Fidel Zavala; Bryce Chackerian
Journal:  NPJ Vaccines       Date:  2021-01-21       Impact factor: 7.344

4.  Avidity of anti-phospholipid antibodies in relation to their levels.

Authors:  Lenka FialovÁ; Oliver KuchaŘ; Milada PetrÁČkovÁ; Ivan Malbohan; TomÁŠ Zima
Journal:  Cent Eur J Immunol       Date:  2020-07-27       Impact factor: 2.085

5.  Humoral immune responses against SARS-CoV-2 Spike variants after mRNA vaccination in solid organ transplant recipients.

Authors:  Alexandra Tauzin; Guillaume Beaudoin-Bussières; Shang Yu Gong; Debashree Chatterjee; Gabrielle Gendron-Lepage; Catherine Bourassa; Guillaume Goyette; Normand Racine; Zineb Khrifi; Julie Turgeon; Cécile Tremblay; Valérie Martel-Laferrière; Daniel E Kaufmann; Héloïse Cardinal; Marc Cloutier; Renée Bazin; Ralf Duerr; Mélanie Dieudé; Marie-Josée Hébert; Andrés Finzi
Journal:  iScience       Date:  2022-08-23

6.  BNT162b2 mRNA SARS-CoV-2 Vaccine Elicits High Avidity and Neutralizing Antibodies in Healthcare Workers.

Authors:  Federico Pratesi; Teresita Caruso; Davide Testa; Tiziano Tarpanelli; Alessandra Gentili; Davide Gioè; Paola Migliorini
Journal:  Vaccines (Basel)       Date:  2021-06-18

7.  Evolution of Anti-RBD IgG Avidity following SARS-CoV-2 Infection.

Authors:  Alexandra Tauzin; Gabrielle Gendron-Lepage; Manon Nayrac; Sai Priya Anand; Catherine Bourassa; Halima Medjahed; Guillaume Goyette; Mathieu Dubé; Renée Bazin; Daniel E Kaufmann; Andrés Finzi
Journal:  Viruses       Date:  2022-03-04       Impact factor: 5.048

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.